Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Cash to Debt Ratio measures the financial strength of a company. It is calculated as a company's cash, cash equivalents, and marketable securities divide by its debt. Shin Nippon Biomedical Laboratories's cash to debt ratio for the quarter that ended in Mar. 2026 was 0.45.
If Cash to Debt ratio is less than 1, the company cannot pay off its debt using the cash in hand. Here we can see, Shin Nippon Biomedical Laboratoriescouldn't pay off its debt using the cash in hand for the quarter that ended in Mar. 2026.
If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. If it is smaller than 1, it means the company has more debt than the cash in hands. In this case, it is important to look the the company's Interest Coverage. Ben Graham requires that a company must have an Interest Coverage of at least 5.
Shin Nippon Biomedical Laboratories Cash-to-Debt Related Terms
Shin Nippon Biomedical Laboratories Cash-to-Debt Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Note: An indication of "No Debt" does not necessarily mean that the company has no debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.
For the Diagnostics & Research subindustry, Shin Nippon Biomedical Laboratories's Cash-to-Debt, along with its competitors' market caps and Cash-to-Debt data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Shin Nippon Biomedical Laboratories Cash-to-Debt vs Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, Shin Nippon Biomedical Laboratories's Cash-to-Debt distribution charts can be found below:
* The bar in red indicates where Shin Nippon Biomedical Laboratories's Cash-to-Debt falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Shin Nippon Biomedical Laboratories (SBLOF) has a Cash-to-Debt of 0.45 as of Mar. 2026. This is 18% above median its historical median of 0.38. Over the past decade, Shin Nippon Biomedical Laboratories' Cash-to-Debt has ranged from 0.28 to 0.77. According to the industry distribution chart, Shin Nippon Biomedical Laboratories ranks #149 out of 209 companies in the Medical Diagnostics & Research industry, placing it in the top 71.3%.
Is Shin Nippon Biomedical Laboratories' Cash-to-Debt too high?
Shin Nippon Biomedical Laboratories' current Cash-to-Debt of 0.45 is 18% above median its 10-year median of 0.38. Over the past 10 years, this metric has ranged from a low of 0.28 to a high of 0.77. The Medical Diagnostics & Research industry median Cash-to-Debt is 1.07. Shin Nippon Biomedical Laboratories' value of 0.45 is 57.9% below this industry median. Based on the distribution chart, Shin Nippon Biomedical Laboratories ranks #149 out of 209 companies in the Medical Diagnostics & Research industry, which is below the industry midpoint. Overall, Shin Nippon Biomedical Laboratories has a GF Score™ of 78/100, reflecting its overall financial health beyond just this single metric.
How does Shin Nippon Biomedical Laboratories' Cash-to-Debt compare to TMO and DHR?
According to the Medical Diagnostics & Research industry distribution chart, Shin Nippon Biomedical Laboratories ranks #149 out of 209 companies for Cash-to-Debt. This places Shin Nippon Biomedical Laboratories in the lower half of its industry. The industry median Cash-to-Debt is 1.07. Shin Nippon Biomedical Laboratories' value of 0.45 is 57.9% below this benchmark. Historically, Shin Nippon Biomedical Laboratories' own Cash-to-Debt has ranged from 0.28 to 0.77 over the past decade. While the company's 10-year median is 0.38 vs. the industry median of 1.07, Shin Nippon Biomedical Laboratories has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cash-to-Debt for a Medical Diagnostics & Research company?
The median Cash-to-Debt among Medical Diagnostics & Research companies is 1.07, based on 209 companies in the industry. Companies in the top quartile (top 25%) have a Cash-to-Debt significantly above this median, while those in the bottom quartile fall well below. However, Cash-to-Debt should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Shin Nippon Biomedical Laboratories's current Cash-to-Debt of 0.45 is 57.9% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cash-to-Debt mean?
A high Cash-to-Debt can signal that a stock is expensive relative to its fundamentals. For the Medical Diagnostics & Research industry, the median Cash-to-Debt is 1.07 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Shin Nippon Biomedical Laboratories's current Cash-to-Debt is 0.45, which is 18% above median its own 10-year median of 0.38. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Shin Nippon Biomedical Laboratories stock overvalued right now?
Shin Nippon Biomedical Laboratories (SBLOF) has a current Cash-to-Debt of 0.45. The stock's GF Value™ is $12.01, compared to a current price of $9.16 — trading 23.7% below its estimated fair value. The current Cash-to-Debt is 0.45, which is 18% above median its 10-year median of 0.38 and 57.9% below the Medical Diagnostics & Research industry median of 1.07. Shin Nippon Biomedical Laboratories' overall GF Score™ is 78/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cash-to-Debt calculated?
Cash-to-Debt is calculated from a company's financial statements. For Shin Nippon Biomedical Laboratories (SBLOF), the current Cash-to-Debt is 0.45 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Shin Nippon Biomedical Laboratories (SBLOF) Overvalued in 2026?
Based on GuruFocus' analysis, Shin Nippon Biomedical Laboratories stock appears to be undervalued.
The current stock price of $9.16 is trading 23.7% below its estimated GF Value™ of $12.01.
Key valuation signals for SBLOF:
Cash-to-Debt: 0.45 (18% above median its 10-year median of 0.38)
GF Value™: $12.01 vs. price of $9.16 (23.7% below fair value)
Industry Position: 57.9% below the Medical Diagnostics & Research median (#149 of 209)
No single metric tells the full story. See the SBLOF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Shin Nippon Biomedical Laboratories Ltd provides pre-clinical testing services in the pharmaceutical industry in Japan. The company provides a range of services such as pre-clinical and analysis studies, contracted clinical trials, SMO, CRO, translational research and cancer treatment.
78GF Score
Get the complete analysis for SBLOF
Cash-to-Debt is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
SBLOF has been successfully added to your 
